The Biocon share rallied over 8% to touch a fresh 52-week high of Rs 444.50 on the NSE. The sharp upstick in the stock came after buzz about a large block deal.
The difference could be seen in the trading volume as well, which skyrocketed 180 times today comparatively. The company’s trading volume (NSE+BSE) stood at 8 crore shares, while the one-month average trading volume is 42 lakh shares.
According to a Reuters report last evening, Mylan, part of a global healthcare company Viatris plans to sell up to 92 million shares in Biocon worth up to Rs 3,481 crore. Reuters report quioting sources had indiocated that the sale could potentially represent up to 5.64% of Biocon’s outstanding shares.
Financialexpress.com could not verify the news independently.
Biocon share price performance
The share price of Biocon has risen 7% in the last five trading days. The stock has given a return of over 5% in the past one month and 15.55% in the last six monts. Biocon’s share price has surged 15% over the previous 12 months.
Biocon Q4FY26 results
The company’s consolidated net profit fell 63% year-on-year to Rs 126 crore in Q4FY26. The company took an exceptional charge of Rs 80 crore during the quarter, mainly related to one-time adjustments and restructuring impacts tied to business integration. However, the net profit before exceptional items surged 64% YoY to Rs 179 crore.
Its operating revenue rose 10% YoY to Rs 4,517 crore in Q4FY26, while EBITDA came in at Rs 1,073 crore, reflecting a 29% increase on a YoY basis, supported by improved product mix and operating leverage.
